Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE 60 versus UROVIST SODIUM 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE 60 versus UROVIST SODIUM 300.
DIATRIZOATE-60 vs UROVIST SODIUM 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Iodinated contrast agent that attenuates X-rays, improving visualization of vascular structures and organs during imaging.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
Intravenous injection of 50-100 mL for contrast imaging, typically a single dose of 300 mg iodine/mL.
None Documented
None Documented
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (GFR >90 mL/min). In renal impairment, half-life may be prolonged up to 10 hours or more, correlating with decreased GFR.
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Primarily renal (glomerular filtration), with >90% of the administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent